Meningococcal ACWY Statewide vaccination program

WA Health is implementing a meningococcal ACWY (MenW) vaccination program for 15 to 19 year olds. This state-funded program will run for three years starting in April 2017 and ending in 2019.  

The program provides vaccination to adolescents aged 15 to 19 years.

  • School immunisation teams will visit secondary schools across WA and provide immunisation for year 10, 11 and 12 students. The majority of these will be completed during term 3 with follow ups during term 4.
  • Aboriginals Medical Services (AMSs) will offer the vaccine throughout 2017.
  • Some metropolitan on-campus university medical centres. 
  • General practitioner (GP) surgeries for:
    • years 10, 11 and 12 students who missed their school or university vaccination
    • adolescents aged 15 to 19 years who are not at school.
Eligible groups
  • 2017: All persons in years 10, 11, or 12 or between the ages of 15-19 are eligible to receive the state-funded vaccine.
  • 2018 and 2019: Only students in year 10 will be eligible, regardless of age.

The consent forms have been distributed to schools and government clinics Statewide.

Where to get vaccinated
  • In schools for year 10 to 12 students
    Schools will send out consent forms prior to immunisation day.
  • Individuals who are 18 to 19 years of age and other age-eligible people not in school
    At some metropolitan university health centres (university students), a GP, or they can contact their Population Health Units (country) or the Central Immunisation Service (metropolitan) to ask how they can receive their vaccine.
Central Immunisation Service
(08) 9321 1312 
8:30am - 4:30pm, Monday to Friday.
  • All 15 to 19 year old Aboriginal and/or Torres Strait Islander persons 
    Vaccines are available throughout 2017 at Aboriginal Medical Services.
Which vaccine is used?

The Nimenrix® (Pfizer) quadrivalent meningococcal conjugate vaccine (4vMenCV) will be used and provides protection for serotypes A, C, W135 and Y.  


One dose is sufficient for most people.

If a person has a condition associated with an increased risk of invasive meningococcal disease (IMD), it is recommended that a booster dose is administered eight weeks after the first dose. The conditions include:

  • defects in or deficiency of complement components, including factor H, factor D or properdin deficiency
  • current or future treatment with eculizumab (a monoclonal antibody directed against complement component C5)
  • functional or anatomical asplenia
  • HIV infection, regardless of stage of disease or CD4+ count
  • haematopoietic stem cell transplant.

The first dose will be available through the school program. Persons who require a second dose will be able to have it administered by their GP. GPs can order doses for this purpose by following the procedure below.

Vaccine orders

Ordering can be done fortnightly. Immunisation providers are encouraged to order only what they think they will need and not over-order because supplies may be limited depending on uptake.


Vaccination reporting

All doses administered must be reported to the Australian Immunisation Register (AIR).

Adverse event reporting

All immunisation providers have a statutory obligation to report all adverse events to the WA Vaccine Safety Surveillance System (WAVSS). Learn how to report.

More information